Back to companies

Glenmark Pharmaceuticals Ltd: Overview

Want to continue viewing company data?

Sign up for exclusive competitive intelligence.
Company Data Subscription $329 per month (billed Annually)
Signup to View Free Sample

Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the discovery and development of new chemical entities (NCEs). It develops and markets branded and generic formulations. The company's formulations business encompasses therapeutic areas such as dermatology, respiratory and oncology. It has also presence in other therapeutic areas such as diabetes, cardiovascular and oral contraceptives. It also offers a wide range of specialty and generic products. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark has manufacturing facilities in India, Argentina, the US and Czech Republic. The company markets its products in North America, Japan, Latin America, Europe, India, MENA, Asia and Russia, among others. Glenmark is headquartered in Mumbai, Maharashtra, India.

Headquarters India

Address B D S Marg, Chakala, Off Western Express Highway, Andheri (E), Mumbai, 400099


Telephone 91 22 40189999

No of Employees 13,390

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange GLENMARK (NSE)

Revenue (2022) $1.7B

EPS XXX

Market Cap* $1.3B

Net Profit Margin (2021) XXX 21.5%

   

* As of and is in US$

Explore premium data & analytics

410+

Marketed Drugs

Understand Glenmark Pharmaceuticals Ltd’s commercialized product portfolio to stay one step ahead of the market.

260+

Clinical Trials

Determine Glenmark Pharmaceuticals Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

70+

Catalyst Calendar

Proactively evaluate Glenmark Pharmaceuticals Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

60+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Glenmark Pharmaceuticals Ltd’s relevant decision makers and contact details.

40+

Pipeline Drugs

Identify which of Glenmark Pharmaceuticals Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

18+

Consumer Market Data Insights

Insight into market share and brand performance.

6

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

3

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

3

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

2

Medical Pipeline Products

A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Services
Branded Formulations: Contract Manufacturing
Oncology
Respiratory
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 New Products/Services In May, the company launched Hello Skin, a Whatsapp based chatbot to help patients suffering from fungal infections.
2022 Regulatory Approval In May, the company received final approval by the United States Food & Drug Administration for Abiraterone Acetate Tablets USP, 500 mg, the generic version of Zytiga 1 Tablets, 500 mg, of Janssen Biotech Inc.
2022 Regulatory Approval In April, the company's Glenmark Specialty S.A. received approval from the Indian drug regulator, Drug Controller General of India (DCGI), to conduct a Phase 1 clinical trial of its novel small-molecule, GRC 54276, a hematopoietic progenitor kinase 1 (HPK1) inhibitor.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Glenmark Pharmaceuticals Ltd Viatris Inc Teva Pharmaceutical Industries Ltd Sun Pharmaceutical Industries Ltd Aurobindo Pharma Ltd
Headquarters India United States of America Israel India India
City Mumbai Canonsburg Tel Aviv Mumbai Hyderabad
State/Province - Pennsylvania Tel Aviv - Telangana
No. of Employees 13,390 37,000 37,037 37,000 19,364
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Glenn Saldanha Managing Director; Chairman Executive Board 2001 -
V.S. Mani Global Chief Financial Officer; Executive Director Executive Board 2017 -
Jayaram Philkana Global Chief Human Resources Officer; President Senior Management - -
Darshan Makhey, Ph.D. President; Chief Quality Officer Senior Management 2012 -
Robert Crockart Chief Commercial Officer, Glenmark Life Sciences Ltd Senior Management - -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer